By N Griffith, A McBride, JG Stevenson, and L Green

 

Pharmacists will play a key role in evaluating biosimilars for formulary inclusion in hospitals around the world. Biosimilars were reviewed and compared in the current European Union and US regulatory pathways for biosimilars. A checklist is proposed containing considerations to ensure that pharmacists thoroughly evaluate future biosimilars for formulary inclusion.